
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Following the global trend of consolidating market positions of clinical research organizations (CROs), Optimapharm acquired the Czech CRO company MKS Research. With this acquirement, Optimapharm hopes to strengthen its clientele across the pharmaceutical and biotech industries all while building revenue.
Read the full release






